New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada - PubMed (original) (raw)
Guideline
. 2000 Feb 2;92(3):205-16.
doi: 10.1093/jnci/92.3.205.
Affiliations
- PMID: 10655437
- DOI: 10.1093/jnci/92.3.205
Guideline
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
P Therasse et al. J Natl Cancer Inst. 2000.
Abstract
Anticancer cytotoxic agents go through a process by which their antitumor activity-on the basis of the amount of tumor shrinkage they could generate-has been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical research combined forces to tackle the review of these criteria on the basis of the experience and knowledge acquired since then. After several years of intensive discussions, a new set of guidelines is ready that will supersede the former criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. This special article also provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate.
Comment in
- Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?
Gehan EA, Tefft MC. Gehan EA, et al. J Natl Cancer Inst. 2000 Feb 2;92(3):179-81. doi: 10.1093/jnci/92.3.179. J Natl Cancer Inst. 2000. PMID: 10655425 No abstract available. - Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB. Vergote I, et al. J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5. doi: 10.1093/jnci/92.18.1534. J Natl Cancer Inst. 2000. PMID: 10995813 No abstract available. - Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Rustin GJ, et al. J Natl Cancer Inst. 2004 Mar 17;96(6):487-8. doi: 10.1093/jnci/djh081. J Natl Cancer Inst. 2004. PMID: 15026475 No abstract available. - PET-CT modification of RECIST guidelines.
O'Connell M. O'Connell M. J Natl Cancer Inst. 2004 May 19;96(10):801-2; author reply 802. doi: 10.1093/jnci/djh149. J Natl Cancer Inst. 2004. PMID: 15150309 No abstract available. - Criticism of tumor response criteria raises trial design questions.
Twombly R. Twombly R. J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086. J Natl Cancer Inst. 2006. PMID: 16478740 No abstract available.
Similar articles
- [New guidelines to evaluate the response to treatment in solid tumors].
Duffaud F, Therasse P. Duffaud F, et al. Bull Cancer. 2000 Dec;87(12):881-6. Bull Cancer. 2000. PMID: 11174117 French. - [New guidelines to evaluate the response to treatment "RECIST"].
Sasaki T. Sasaki T. Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84. Gan To Kagaku Ryoho. 2000. PMID: 11142160 Review. Japanese. - Tumor response evaluation in oncology: current update.
Shanbhogue AK, Karnad AB, Prasad SR. Shanbhogue AK, et al. J Comput Assist Tomogr. 2010 Jul;34(4):479-84. doi: 10.1097/RCT.0b013e3181db2670. J Comput Assist Tomogr. 2010. PMID: 20657213 Review. - Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K. Park JO, et al. Jpn J Clin Oncol. 2003 Oct;33(10):533-7. doi: 10.1093/jjco/hyg093. Jpn J Clin Oncol. 2003. PMID: 14623923 - Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R, Llovet JM. Lencioni R, et al. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Semin Liver Dis. 2010. PMID: 20175033 Review.
Cited by
- Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
Cunningham D, Wong RP, D'Haens G, Douillard JY, Robertson J, Stone AM, Van Cutsem E; HORIZON I study group. Cunningham D, et al. Br J Cancer. 2013 Feb 19;108(3):493-502. doi: 10.1038/bjc.2012.545. Epub 2013 Jan 8. Br J Cancer. 2013. PMID: 23299530 Free PMC article. Clinical Trial. - Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Lambertini M, et al. Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099741 Free PMC article. - Efficacy of Preoperative Chemotherapy in Treatment of Children With Wilms' Tumor: A Meta-Analysis.
Junjun J, Xuelian Z, Dhruba K, Haiyang X, Lin Z, Shusen Z. Junjun J, et al. Iran J Pediatr. 2015 Apr;25(2):e366. doi: 10.5812/ijp.366. Epub 2015 Apr 18. Iran J Pediatr. 2015. PMID: 26196000 Free PMC article. - Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival.
Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, Pawlik TM, Diaz LA, Bhagat N, Eng J, Geschwind JF, Kamel IR. Gowdra Halappa V, et al. Radiology. 2013 Feb;266(2):502-13. doi: 10.1148/radiol.12120495. Epub 2012 Nov 28. Radiology. 2013. PMID: 23192780 Free PMC article. - Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Naing A, et al. Clin Cancer Res. 2012 May 1;18(9):2625-31. doi: 10.1158/1078-0432.CCR-12-0061. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465830 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources